Veracyte, Inc.
VCYT
$44.65
-6.34%
Veracyte, Inc. is a genomic diagnostics company that develops and commercializes molecular tests designed to improve diagnosis and treatment decisions across cancer and other diseases, with a portfolio spanning thyroid (Afirma), prostate (Decipher Prostate), breast (Prosigna), and bladder (Decipher Bladder) cancers. The company occupies a distinct position as a specialized, evidence-driven diagnostics platform rather than a broad life-sciences tools provider, competing with larger players such as Natera, Exact Sciences, and Illumina in the molecular diagnostics arena. The current investor narrative centers on whether Veracyte can sustain the sharp revenue momentum that drove a dramatic mid-2026 re-rating, followed by a volatile pullback that has left the stock roughly 25% below its 52-week high despite a still-positive one-year gain. Attention is also focused on the durability of its margin expansion and cash generation, the competitive threat from Natera's expanding MRD franchise (including its recent Japan PMDA approval for bladder cancer), and the stock's unusually high short interest, which amplifies both downside risk and squeeze potential.…
VCYT
Veracyte, Inc.
$44.65
Related headlines
Investment Opinion: Should I buy VCYT Today?
Based on the synthesized data, Veracyte receives a Hold rating with a bullish bias. The core thesis is that the company's strong gross margin (69.62%), fortress balance sheet (D/E 0.03), and analyst expectations of an earnings inflection (forward EPS $2.38) provide a solid foundation, but the recent momentum breakdown (-24.90% over 3 months) and premium valuation (PS 6.40x) warrant caution. The consensus 'buy' rating and average target price of $58.42 imply 28.6% upside, but the wide target range ($44-$70) reflects high uncertainty.
Supporting evidence for the Hold rating includes: 1) Revenue is estimated to reach $945.7 million, which would represent meaningful growth from current levels, though the exact growth rate cannot be calculated without historical data. 2) Gross margin of 69.62% is robust and provides operating leverage potential. 3) The forward P/E of 23.29x is reasonable if earnings materialize, but the trailing P/E of 50.12x and EV/EBITDA of 33.31x indicate the stock is not cheap. 4) The PEG ratio of 0.31 suggests the stock may be undervalued relative to its growth prospects, but this metric is sensitive to the reliability of growth estimates. 5) The balance sheet is a clear strength with negligible debt and a current ratio of 8.15.
The biggest risks that could invalidate the thesis are: 1) A failure to achieve the estimated EPS of $2.38, which would leave the stock overvalued and could trigger a decline toward the 52-week low of $29.455. 2) Competitive pressure from Natera's MRD franchise, particularly in bladder cancer, which could slow Veracyte's revenue growth. 3) A broader market downturn or sector rotation away from high-beta growth stocks, given the beta of 1.926. The rating would upgrade to Buy if the stock pulls back to the $40-$42 support zone or if the company demonstrates accelerating revenue growth and margin expansion. It would downgrade to Sell if revenue growth decelerates below 10% or if gross margins fall below 65%. Relative to its own history and peers, the stock appears fairly valued to slightly overvalued, but the forward multiple suggests that much of the optimism is already priced in.
Sign up to view all
VCYT 12-Month Price Forecast
Veracyte presents a balanced risk/reward profile. The company's strong gross margin and fortress balance sheet are offset by a premium valuation and thin trailing profitability. The analyst consensus is bullish, but the wide target range and recent momentum breakdown suggest caution. The base case (50% probability) sees the stock recovering toward $58.42 as earnings improve, but the bear case (20% probability) could see a retest of the 52-week low if execution falters. I would upgrade to bullish if the company reports two consecutive quarters of accelerating revenue growth and margin expansion, and downgrade to bearish if gross margins fall below 65% or if revenue growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Veracyte, Inc.'s 12-month outlook, with a consensus price target around $58.42 and implied upside of +30.8% versus the current price.
Average Target
$58.42
0 analysts
Implied Upside
+30.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $70
Analyst target range
Coverage is solid, with 12 analysts following Veracyte and a consensus recommendation of "buy" (recommendation mean of 1.62, where lower is more bullish). The average target price is $58.42, which implies roughly +28.6% upside from the current price of $45.43, a spread that signals meaningful analyst confidence despite the recent selloff. The consensus leans bullish, supported by estimated EPS of $2.38 and estimated revenue of about $945.7 million, both of which underpin the view that the current pullback is a buying opportunity rather than a fundamental breakdown.
The target range runs from a low of $44.00 to a high of $70.00, a wide $26 spread that reflects genuine disagreement about the company's trajectory. The low target of $44.00 is essentially at the current price, implying that the most cautious analysts see the stock as fully valued and price in slower growth or margin pressure, while the high target of $70.00 assumes successful execution on the earnings inflection, multiple expansion, and possibly new product or reimbursement catalysts. The wide spread signals high uncertainty — consistent with the 1.93 beta and 6.68 short ratio — and means position sizing should account for the possibility that the bear case is already close to being priced in. Notably, no institutional ratings history is provided, so it is not possible to determine whether analysts have been recently upgrading or downgrading; the static snapshot shows a constructive but not uniformly convinced analyst community.
Bulls vs Bears: VCYT Investment Factors
The bull case rests on Veracyte's strong gross margin (69.62%), fortress balance sheet (D/E 0.03), and analyst expectations of a doubling in EPS to $2.38, which would compress the forward P/E to 23.29x. The bear case highlights the sharp momentum reversal (-24.90% over 3 months), premium valuation (PS 6.40x, EV/EBITDA 33.31x), and competitive threats from Natera. Currently, the bear evidence appears slightly stronger given the recent price action and the fact that the stock trades at a premium despite thin trailing profitability. The single most important tension is whether Veracyte can deliver the earnings inflection that the forward multiple assumes; if it does, the stock could re-rate toward the analyst average target of $58.42, but any shortfall could trigger a decline toward the 52-week low of $29.455.
Bullish
- Analyst consensus sees 28.6% upside: 12 analysts cover VCYT with a consensus 'buy' rating (mean 1.62) and an average target price of $58.42, implying +28.6% upside from the current $45.43. The high target of $70.00 suggests some analysts see even greater potential if the earnings inflection materializes.
- Forward P/E compression signals earnings inflection: The trailing P/E of 50.12x drops to a forward P/E of 23.29x based on estimated EPS of $2.38, implying the market expects earnings to roughly double. This steep compression suggests that if Veracyte delivers on consensus, the valuation normalizes quickly.
- Fortress balance sheet with negligible debt: Debt-to-equity is only 0.0303 and the current ratio is 8.15, indicating abundant liquidity and virtually no leverage. This allows Veracyte to fund growth internally and weather economic downturns without financial distress.
- High gross margin provides operating leverage: Gross margin stands at 69.62%, well above the net margin of 12.83% and operating margin of 14.34%. As revenue scales toward the estimated $945.7 million, this gross margin advantage could drive significant bottom-line expansion.
Bearish
- Momentum has sharply reversed: While the stock is up 38.42% over the past year, it has fallen 24.90% over the past three months, significantly lagging the S&P 500's +5.81% gain. The recent -6.41% single-day drop on elevated volume suggests sellers remain in control.
- Valuation is rich on most metrics: The trailing P/E of 50.12x, PS ratio of 6.40x, and EV/EBITDA of 33.31x are premium multiples that require flawless execution. The PCF ratio of 24.27 also indicates the company is not yet generating cash flow commensurate with its valuation.
- Thin profitability limits margin for error: Trailing EPS is just $0.02, resulting in a net margin of 12.83% and ROE of only 5.07%. Any revenue shortfall or margin compression could quickly erase earnings and undermine the forward P/E assumption.
- Competitive threat from Natera's MRD expansion: Natera's Signatera recently won Japan PMDA approval for bladder cancer, directly challenging Veracyte's Decipher Bladder franchise. Natera's growing MRD leadership could pressure Veracyte's market share and pricing power.
VCYT Technical Analysis
Veracyte is in a recovery-and-consolidation phase following an extraordinary run: the stock is up 38.42% over the past year, yet at $45.43 it sits only about 51% of the way through its 52-week range of $29.455 to $60.91, meaning it has given back a substantial portion of its earlier gains. The 6-month change of +51.38% confirms the powerful intermediate uptrend, but the 3-month change of -24.90% shows that momentum has decisively reversed, leaving the stock in a wide, volatile range rather than a clean trend. This positioning suggests neither a fresh breakout nor a capitulation low, but rather a market that is re-pricing the name after an overextended advance.
Short-term momentum is mixed and fragile. The 1-month change of +2.57% is modestly positive and actually beats the S&P 500's +0.69% over the same period, producing a relative strength of +1.88, but the most recent session saw a sharp -6.41% single-day drop from $48.54 to $45.43 on elevated volume of about 1.73 million shares. That kind of high-volume reversal after a bounce toward the high-$40s suggests sellers remain active on rallies, and the 3-month relative strength of -30.71 versus the S&P's +5.81% underscores how badly the stock has lagged since late June. The divergence between the strong 1-year trend and the weak 3-month trend is a classic deceleration signal that warrants caution until price can reclaim the mid-$50s.
Key technical levels are well defined. Support rests near the 52-week low of $29.455, with a secondary zone around the August lows near $40.68-$41.25; resistance sits at the 52-week high of $60.91, with intermediate supply around $56-$60 where the stock repeatedly stalled in July. A breakout above $60.91 would signal renewed institutional accumulation and likely open a move toward new highs, while a breakdown below $40 would confirm the downtrend and put the $29.455 low in play. With a beta of 1.926, Veracyte is nearly twice as volatile as the broad market, and the maximum drawdown of -39.23% illustrates the real risk of outsized position sizing; the short ratio of 6.68 days also means any positive catalyst could trigger a sharp squeeze, adding two-sided volatility.
Beta
1.95
1.95x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$29-$61
Price range past year
Annual Return
+23.9%
Cumulative gain past year
| Period | VCYT Return | S&P 500 |
|---|---|---|
| 1m | +5.0% | +1.2% |
| 3m | -20.4% | +4.5% |
| 6m | +42.4% | +14.6% |
| 1y | +23.9% | +16.0% |
| ytd | +5.3% | +14.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VCYT Fundamental Analysis
Veracyte's growth trajectory remains the core of the investment case, though the provided dataset does not include quarterly revenue history or segment breakdowns, so the multi-quarter trend cannot be verified directly. What is available is forward-looking: analysts model estimated revenue of approximately $945.7 million (range $925.4M-$964.9M) and estimated EPS of $2.38 (range $2.31-$2.44), which implies the company is expected to scale meaningfully from current levels. The absence of reported quarterly financials in this dataset is a limitation, but the consensus revenue estimate near $946 million, combined with a market cap of roughly $3.31 billion, implies a price-to-sales ratio of about 6.4x, consistent with a growth diagnostics company being valued on future revenue expansion rather than current earnings power.
Profitability is genuine but thin relative to the valuation. Trailing EPS is just $0.02, producing a trailing P/E of about 50.1x, while the net margin is 12.83% and the operating margin is 14.34% — respectable for a diagnostics company but far below the gross margin of 69.62%, indicating that sales, R&D, and administrative costs consume the majority of gross profit. ROE of 5.07% and ROA of 4.09% are modest, reflecting a capital-light but still sub-scale earnings base; the forward P/E of 23.29x versus the trailing 50.12x implies the market expects EPS to roughly double, consistent with the $2.38 consensus estimate versus the current $0.02 trailing figure. Margin expansion is therefore the key swing factor: if the 69.62% gross margin can be leveraged against a growing revenue base, operating leverage could drive the earnings inflection the forward multiple assumes.
The balance sheet is a clear strength. Debt-to-equity is only 0.0303, and the current ratio of 8.15 indicates abundant short-term liquidity, meaning Veracyte funds its growth internally rather than through leverage. However, the price-to-cash-flow ratio of 24.27 and EV/EBITDA of 33.31 suggest the company is not yet generating cash flow commensurate with its valuation, and the absence of detailed cash flow statement data prevents a precise free cash flow yield calculation. The combination of negligible debt, high liquidity, and a 12.83% net margin paints a picture of a financially stable company whose valuation depends on converting its gross margin advantage into durable bottom-line growth.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VCYT Overvalued?
Because Veracyte's trailing net income is positive (EPS of $0.02), the P/E ratio is the appropriate primary metric, though the tiny earnings base makes it a noisy one. The trailing P/E of 50.12x versus a forward P/E of 23.29x is a dramatic gap that implies the market expects earnings to roughly double, consistent with the $2.38 consensus EPS estimate versus the current $0.02 trailing figure. This steep compression from trailing to forward multiple signals that investors are underwriting a significant profitability inflection rather than paying up for current earnings.
On a peer-comparison basis, the data provided does not include an explicit industry-average multiple, so a precise premium or discount cannot be quantified from the supplied dataset. However, the available multiples — PS of 6.40x, EV/Sales of 6.15x, EV/EBITDA of 33.31x, and P/B of 2.53x — are consistent with a premium-valued molecular diagnostics growth company, particularly given the 69.62% gross margin and 12.83% net margin. The PEG ratio of 0.31 is notably low, suggesting that when growth is factored in, the stock may not be as expensive as its headline P/E implies, though this metric is sensitive to the reliability of the growth estimate.
Historical ratio data is not available in this dataset, so the current valuation cannot be directly compared to Veracyte's own historical PE or PS band. That said, the forward P/E of 23.29x against a trailing P/E of 50.12x, combined with a PS of 6.40x, suggests the stock is priced for execution: if the company delivers the implied earnings growth, the valuation normalizes quickly, but any shortfall would leave the shares exposed given the 1.93 beta and 39.23% maximum drawdown. Investors should treat the forward multiple as a conditional valuation contingent on margin expansion and revenue delivery.
PE
50.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.3x
Enterprise Value Multiple
Investment Risk Disclosure
Veracyte's financial risks are moderate but centered on its thin earnings base and premium valuation. Trailing EPS is only $0.02, resulting in a net margin of 12.83% and ROE of 5.07%, which leaves little cushion if revenue growth slows. The forward P/E of 23.29x assumes EPS will jump to $2.38, a more than 100-fold increase from trailing levels; any miss on this estimate could cause a sharp de-rating. While the balance sheet is strong with debt-to-equity of 0.0303 and a current ratio of 8.15, the price-to-cash-flow ratio of 24.27 indicates that cash generation is not yet commensurate with the valuation, and the absence of detailed cash flow data prevents a precise assessment of free cash flow sustainability.
Market and competitive risks are significant. The stock's beta of 1.926 means it is nearly twice as volatile as the broad market, amplifying downside during sector rotations. The recent news of Natera's Signatera winning Japan PMDA approval for bladder cancer poses a direct threat to Veracyte's Decipher Bladder franchise, potentially eroding market share and pricing power. Additionally, the stock trades at a premium to the broader market (PS of 6.40x, EV/EBITDA of 33.31x), leaving it vulnerable to multiple compression if growth expectations are not met. The 3-month relative strength of -30.71 versus the S&P 500's +5.81% highlights how quickly sentiment has deteriorated, and the high short ratio of 6.68 days adds to the volatility.
The worst-case scenario would involve a combination of slowing revenue growth, margin compression, and competitive losses. If Veracyte fails to achieve the estimated EPS of $2.38, the stock could retest its 52-week low of $29.455, representing a decline of approximately 35% from the current price of $45.43. The analyst low target of $44.00 is only slightly below the current price, suggesting that the bear case may already be partially priced in, but a more severe outcome could see the stock fall to the 52-week low if the company reports disappointing results or loses key contracts. Given the maximum drawdown of -39.23% over the past year, investors should be prepared for significant volatility and potential losses in an adverse scenario.
FAQ
The key risks of holding VCYT include: 1) Earnings execution risk: The forward P/E of 23.29x assumes EPS will jump to $2.38, but trailing EPS is only $0.02, leaving little room for error. 2) Competitive risk: Natera's Signatera recently received Japan PMDA approval for bladder cancer, directly threatening Veracyte's Decipher Bladder franchise and potentially eroding market share. 3) Valuation risk: The stock trades at a premium (PS 6.40x, EV/EBITDA 33.31x), and any slowdown in growth could trigger a de-rating. 4) Volatility risk: With a beta of 1.926 and a maximum drawdown of -39.23%, the stock is nearly twice as volatile as the market, and the high short ratio of 6.68 days amplifies both upside and downside moves. These risks are ranked from highest to lowest severity, with earnings execution being the most critical.
The 12-month forecast for VCYT includes three scenarios: a bull case (30% probability) with a target range of $58.42-$70.00, a base case (50% probability) with a target range of $50.00-$58.42, and a bear case (20% probability) with a target range of $29.455-$44.00. The base case is most likely, assuming revenue grows to $945.7 million and EPS improves to near $2.38, leading the stock to recover toward the analyst average target of $58.42. The bull case requires successful execution and multiple expansion, while the bear case would involve earnings misses and competitive losses. The key assumption behind the base case is that Veracyte can sustain its gross margin above 68% and deliver on its earnings guidance.
VCYT appears fairly valued to slightly overvalued on trailing metrics but could be undervalued if forward estimates are met. The trailing P/E of 50.12x is high, but the forward P/E of 23.29x is more reasonable, implying that the market expects earnings to roughly double to $2.38. The PS ratio of 6.40x and EV/EBITDA of 33.31x are premium multiples, but the PEG ratio of 0.31 suggests that when growth is factored in, the stock may not be as expensive as it seems. Compared to peers in molecular diagnostics, Veracyte's gross margin of 69.62% is strong, but its net margin of 12.83% is relatively thin. The market is pricing in significant execution, and any shortfall could lead to multiple compression. Without historical valuation data, it's difficult to say whether the stock is overvalued relative to its own history, but the forward multiple suggests that much of the optimism is already priced in.
VCYT is a good buy for investors with a high risk tolerance and a long-term horizon, but it is not without significant risks. The stock trades at $45.43, with analysts projecting a 28.6% upside to their average target of $58.42, and the forward P/E of 23.29x suggests that earnings are expected to grow substantially. However, the trailing P/E of 50.12x and PS ratio of 6.40x indicate that the stock is not cheap, and the recent 24.90% three-month decline shows that momentum has turned negative. The biggest downside risk is a failure to achieve the estimated EPS of $2.38, which could send the stock back toward its 52-week low of $29.455. For those who believe in the company's ability to execute on its earnings inflection and can stomach the 1.926 beta, VCYT offers a compelling risk/reward, but position sizing should be conservative.
VCYT is more suitable for long-term investment than short-term trading, given its high volatility and the need for patience as the company executes on its earnings inflection. The stock does not pay a dividend (payout ratio 0), so returns depend entirely on capital appreciation. The beta of 1.926 and maximum drawdown of -39.23% make it risky for short-term traders, but the long-term growth potential in molecular diagnostics could reward investors who hold through volatility. A suggested minimum holding period is 2-3 years to allow for the earnings inflection to materialize and for the market to recognize the company's progress. Short-term traders might find opportunities around earnings announcements or news catalysts, but they should be prepared for sharp swings.